Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine to prevent etomidate-induced myoclonus and rocuronium-induced withdrawal during rapid sequence induction
ChiCTR2300068168Phase 4Not yet recruiting
- Sponsor
- Funing County People's Hospital
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in etomidate-induced myoclonus (EIM), Not applicable and Withdrawal movement (2 arms), sponsored by Funing County People's Hospital. Primary endpoints: Frequency and severity of myoclonus after injection of etomidate and Frequency and severity of withdrawal movements after injection of rocuronium. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
etomidate-induced myoclonus (EIM)Not applicableWithdrawal movement
Beyond the preview
Go deeper on ChiCTR2300068168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068168.